title: Inhibition of cold insolubility of an IgA cryoglobulin by decanedicarboxylic acid and related compounds.
abstract: Cold insolubility of a serum IgA cryoimmunoglobulin was found to be inhibited by the addition of 1.5 mM sodium decanedicarboxylate in vitro. The patient with the cryoglobulin had advanced multiple myeloma complicated by severe hyperviscosity that caused lethargy and episodic loss of consciousness. Decanedicarboxylic acid administered orally resulted in transient relief of symptoms and the loss of cryoprecipitability of the paraprotein. Further in vitro studies revealed that sodium salts of long-chain monocarboxylic acids with a minimum of eight carbons, and dicarboxylic acids with a minimum of 12 carbons inhibited cryoprecipitation. Salts of short-chain carboxylic acids, by contrast, enhanced cryoprecipitation. Sodium phenolate and sodium salts of benzoic acid, 2,4-DNP, phenylpropionic acid, and salicylic acid were also inhibitory. These latter compounds, which have a ring structure, did not cause precipitation at any concentration. It was demonstrated that the presence of a free carboxylic group was required for these activities; conversion of carboxylic acid to amide resulted in the loss of both the inhibitory and cryoprecipitation-enhancing effects. Normal plasma, or plasma from five other patients who had IgG, IgM, or mixed-type cryoglobulinemia, were not affected by any of these compounds. It is suggested that in selected cases of hyperviscosity syndrome associated with cryoglobulinemia, some of these compounds, especially monocarboxylic acids with appropriate chain lengths, or those with a ring structure, may have therapeutic applications.
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000368:Aged; D002208:Caproates / Q000494:pharmacology; D003080:Cold Temperature; D003450:Cryoglobulins; D003652:Decanoic Acids / Q000494:pharmacology; D003998:Dicarboxylic Acids / Q000494:pharmacology*; D005559:Formamides / Q000494:pharmacology; D006801:Humans; D007070:Immunoglobulin A; D008297:Male; D009101:Multiple Myeloma / Q000628:therapy; D010654:Phenylbutyrates / Q000494:pharmacology; D010951:Plasma Exchange; D012995:Solubility
chemical_list: D000081:Acetamides; D002208:Caproates; D003450:Cryoglobulins; D003652:Decanoic Acids; D003998:Dicarboxylic Acids; D005559:Formamides; D007070:Immunoglobulin A; D010654:Phenylbutyrates; C036836:dodecanedioic acid